Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the<sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the<sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer

PET/CT with the new <sup>68</sup>Ga-labeled minigastrin analog DOTA-dGlu-Ala-Tyr-Gly-Trp-(<i>N</i>-Me)Nle-Asp-1-Nal-NH<sub>2</sub> (<sup>68</sup>Ga-DOTA-MGS5) was performed on patients with advanced medullary thyroid cancer (MTC) to evaluate cholecysto...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autors principals:	Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klinger, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo di Santo, Irene Virgolini
Format:	Artigo
Idioma:	anglès
Publicat:	2023
Accés en línia:	https://doi.org/10.2967/jnumed.122.264977 https://jnm.snmjournals.org/content/jnumed/64/6/859.full.pdf
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Automated Synthesis of (68)Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting
per: Hörmann, Anton Amadeus, et al.
Publicat: (2022)

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
per: Hörmann, Anton A., et al.
Publicat: (2021)

Preclinical Evaluation of (68)Ga-DOTA-Minigastrin for the Detection of Cholecystokinin-2/Gastrin Receptor–Positive Tumors
per: Brom, Maarten, et al.
Publicat: (2011)

<sup>68</sup>Ga-DOTA-Tyr<sup>3</sup>-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide Therapy
per: Michael Gabriel, et al.
Publicat: (2009)

Bone Metastases in Patients with Neuroendocrine Tumor: <sup>68</sup>Ga-DOTA-Tyr<sup>3</sup>-Octreotide PET in Comparison to CT and Bone Scintigraphy
per: Daniel Putzer, et al.
Publicat: (2009)

DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use
per: Klingler, Maximilian, et al.
Publicat: (2019)

DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use
per: Maximilian Klingler, et al.
Publicat: (2018)

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
per: Michael Gabriel, et al.
Publicat: (2007)

Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification
per: Alexander Kroiss, et al.
Publicat: (2012)

Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog <sup>177</sup>Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
per: Alexander Sauter, et al.
Publicat: (2018)

Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUV(max) reference range for management of pancreatic neuroendocrine tumours
per: Virgolini, Irene, et al.
Publicat: (2016)

Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle
per: Nilica, Bernhard, et al.
Publicat: (2016)

Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle
per: Bernhard Nilica, et al.
Publicat: (2016)

Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for (68)Ga-PSMA-11 PET/CT
per: Uprimny, Christian, et al.
Publicat: (2021)

The Search for an Alternative to [<sup>68</sup>Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of <sup>18</sup>F-labeled Somatostatin Analog Development
per: Christopher M. Waldmann, et al.
Publicat: (2019)

Head-to-Head Comparison of <sup>68</sup>Ga-DOTA-JR11 and <sup>68</sup>Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
per: Wenjia Zhu, et al.
Publicat: (2019)

Localization of Hidden Insulinomas with <sup>68</sup>Ga-DOTA-Exendin-4 PET/CT: A Pilot Study
per: Kwadwo Antwi, et al.
Publicat: (2015)

Comprehensive Quality Control of the ITG <sup>68</sup>Ge/<sup>68</sup>Ga Generator and Synthesis of <sup>68</sup>Ga-DOTATOC and <sup>68</sup>Ga-PSMA-HBED-CC for Clinical Imaging
per: Alejandro Amor‐Coarasa, et al.
Publicat: (2016)

Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT
per: Bayerschmidt, Steffen, et al.
Publicat: (2021)

<sup>68</sup>Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with <sup>18</sup>F-FDG PET/CT
per: Chunxia Qin, et al.
Publicat: (2021)

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting
per: Klingler, Maximilian, et al.
Publicat: (2018)

Preclinical Comparative Study of <sup>68</sup>Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA
per: Sangeeta Ray Banerjee, et al.
Publicat: (2016)

Exploiting the Concept of Multivalency with (68)Ga- and (89)Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression
per: Summer, Dominik, et al.
Publicat: (2018)

Repetitive Early<sup>68</sup>Ga-FAPI PET Acquisition Comparing<sup>68</sup>Ga-FAPI-02,<sup>68</sup>Ga-FAPI-46, and<sup>68</sup>Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions
per: Frederik M. Glatting, et al.
Publicat: (2022)

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum
per: Klingler, Maximilian, et al.
Publicat: (2019)

<sup>68</sup> Ga-DOTA-GGNle-CycMSH <sub>hex</sub> targets the melanocortin-1 receptor for melanoma imaging
per: Jianquan Yang, et al.
Publicat: (2018)

Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m
per: Klingler, Maximilian, et al.
Publicat: (2019)

<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the<sup>68</sup>Ga-FAPI PET Observational Trial
per: Lukas Kessler, et al.
Publicat: (2023)

<sup>68</sup>Ga-DOTATOC Versus <sup>68</sup>Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
per: Thorsten D. Poeppel, et al.
Publicat: (2011)

Comparative Biodistribution and Radiation Dosimetry of <sup>68</sup>Ga-DOTATOC and <sup>68</sup>Ga-DOTATATE in Patients with Neuroendocrine Tumors
per: Mattias Sandström, et al.
Publicat: (2013)

Prospective of <sup>68</sup>Ga-Radiopharmaceutical Development
per: Irina Velikyan
Publicat: (2014)

Comparison of <sup>68</sup>Ga-DOTANOC and <sup>68</sup>Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors
per: Damian Wild, et al.
Publicat: (2013)

Quantitative and Qualitative Intrapatient Comparison of <sup>68</sup>Ga-DOTATOC and <sup>68</sup>Ga-DOTATATE: Net Uptake Rate for Accurate Quantification
per: Irina Velikyan, et al.
Publicat: (2013)

Ethanol-Based Post-processing of Generator-Derived <sup>68</sup>Ga Toward Kit-Type Preparation of <sup>68</sup>Ga-Radiopharmaceuticals
per: Elisabeth Eppard, et al.
Publicat: (2014)

<sup>68</sup>Ga or<sup>18</sup>F for Prostate Cancer Imaging?
per: Claudia Kesch, et al.
Publicat: (2017)

Performance of <sup>68</sup>Ga-DOTA–Conjugated Somatostatin Receptor–Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis
per: Sangwon Han, et al.
Publicat: (2018)

Functional imaging of neuroendocrine tumors with combined PET/CT using <sup>68</sup>Ga‐DOTATATE (DOTA‐<scp>D</scp>Phe<sup>1</sup>,Tyr<sup>3</sup>‐octreotate) and <sup>18</sup>F‐FDG
per: Irfan Kayani, et al.
Publicat: (2008)

Measured Human Dosimetry of<sup>68</sup>Ga-DOTATATE
per: Ronald C. Walker, et al.
Publicat: (2013)

<sup>68</sup>Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the <sup>68</sup>Ga-FAPI PET Prospective Observational Trial
per: Lukas Kessler, et al.
Publicat: (2021)

Evaluation of <sup>68</sup>Ga- and <sup>177</sup>Lu-DOTA-PEG<sub>4</sub>-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma
per: Wissam Beaino, et al.
Publicat: (2015)